Receptor News and Research

RSS

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio AB announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

26 Jun 2013

Lung cancer in women more frequently associated with EGFR mutation and ER expression

The incidence of lung cancer in women affects an estimated 516,000 women worldwide, of which 100,000 are in the United States and 70,000 in Europe. Until now, lung cancers occurring in women have been treated similarly to lung cancers in men. However, numerous studies have highlighted different characteristics of lung cancer in women.

26 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Scientist discovers key mutations that sparked hormonal revolution 500 million years ago

Evolution, it seems, sometimes jumps instead of crawls. A research team led by a University of Chicago scientist has discovered two key mutations that sparked a hormonal revolution 500 million years ago.

25 Jun 2013

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Rural women with breast cancer are less likely than their urban counterparts to receive recommended radiation therapy after having a lumpectomy, a breast-sparing surgery that removes only tumors and surrounding tissue, a study by Mayo Clinic and others found.

25 Jun 2013

Study recommends depression screening In AF clinics

Electrophysiologists (EPs) rate the quality of life of patients with Paroxysmal atrial fibrillation (AF) significantly better than the patients themselves do, with the greatest level of disagreement about mental health.

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Duke Medicine researchers have identified a receptor in the nervous system that may be key to preventing epilepsy following a prolonged period of seizures.

21 Jun 2013

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.

21 Jun 2013

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients.

20 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Researchers develop method to identify aggressive prostate cancers

Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic interaction between single nucleotide polymorphisms. The goal is to better predict a prostate cancer's aggressiveness to avoid unnecessary radical treatment.

20 Jun 2013

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.

19 Jun 2013

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

Blocking B1R receptor activity in brains of Alzheimer's mice recovers memory and cerebrovascular function

A new study shows that memory pathology in older mice with Alzheimer's disease can be reversed with treatment. The study by researchers from the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and at Universit- de Montr-al found that blocking the activity of a specific receptor in the brain of mice with advanced Alzheimer's disease (AD) recovers memory and cerebrovascular function.

18 Jun 2013

Missing brain enzyme increases concentrations of protein related to pain-killer addiction

A missing brain enzyme increases concentrations of a protein related to pain-killer addiction, according to an animal study. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Pyrvinium pamoate inhibits drug-resistant prostate cancer

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

17 Jun 2013

Receptor News and Research

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Lung cancer in women more frequently associated with EGFR mutation and ER expression

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Scientist discovers key mutations that sparked hormonal revolution 500 million years ago

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Study recommends depression screening In AF clinics

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Researchers develop method to identify aggressive prostate cancers

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

Blocking B1R receptor activity in brains of Alzheimer's mice recovers memory and cerebrovascular function

Missing brain enzyme increases concentrations of protein related to pain-killer addiction

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

Pyrvinium pamoate inhibits drug-resistant prostate cancer

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News